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Supplementary Data 
 
Production of drug-bound nanoparticles 
The drugs Gap26, MitoQ, PPADS and C17 were adsorbed by hydrophobic and electrostatic 
interaction with NPs consisting of an amphiphilic copolymer of poly(γ-glutamic acid) and L-
phenylalanine ethylester (γ-PGA-Phe NPs). The adsorption efficiency of the drug was 30-
45% (Supplementary Fig 1a), with the amount adsorbed depending on its initial concentration 
(Supplementary Fig 1b,c). The sizes of Gap26 (50 μg/1mg NP), MitoQ (45 μg/1mg NP) and 
C17 (20 μg/1mg NP)-adsorbed NPs were 260 nm (polydispersity index PDI = 0.14), 180 nm 
(PDI = 0.09) and 220 nm (PDI = 0.08), respectively. The drug-adsorbed NPs showed a 
negative zeta potential (-20 mV) in PBS possibly due to the ionized carboxyl groups of γ-
PGA on the NP surfaces. The NPs were stable under physiological conditions, exhibiting no 
aggregation, precipitation, or dissociation for at least 6 weeks. We observed a sustained 
release of the drug from NPs into PBS and tissue culture medium containing serum 
(Supplementary Fig 1d,e).  
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Effects of drug-bound nanoparticles on signalling through barriers in vitro 
We investigated whether NP-bound drugs, like the drugs in their soluble form, would be able 
to prevent damaging secretions from bilayered BeWo barriers, a model of trophoblast 
barriers, in response to adverse stimuli. BeWo barriers were exposed in vitro to altered 
oxygenation, as a stimulus that would be relevant to fetal development, with and without 
administration of different drug-bound NPs. We tested the effects of culture media 
conditioned by BeWo barriers on fibroblasts (Supplementary Fig S2a,b) and dissociated 
neurons from embryonic cerebral cortex (Supplementary Fig S2c). As noted previously40,41,43, 
the conditioned medium caused DNA damage in fibroblasts and dendrite shortening in 
neurons. Both types of damage have relevance to the biology of psychological disorders96-98. 
In all cases the damage was almost completely prevented by applying MitoQ-NPs to the 
barriers or explants at the start of the hypoxia/reoxygenation exposure (Supplementary Fig 
S2a-c). Gap26-NPs were also effective in preventing damage to fibroblasts and neurons 
mediated by indirect hypoxia-reoxygenation (Supplementary Fig S2a-c). Both NP-bound 
MitoQ and Gap26 were as effective as the soluble drugs (Supplementary Fig S2b)40,41. 
Unloaded NPs were ineffective (Supplementary Fig S2b). Dendrite shortening was also 
prevented by MitoQ-NPs and Gap 26-NPs when BeWo barriers were exposed to the toxic 
benzene metabolites benzoquinone and hydroquinone (Supplementary Fig S2d). Again 
unloaded NPs were ineffective. NPs bound to PPADS were least effective at preventing cell 
damage (Supplementary Fig S2a,c). 
To confirm that the NPs did not cause these changes by passing through the barriers, we 
exposed cortical cells (Supplementary Fig S2e-h) or fibroblasts (Supplementary Fig S2i,j) 
directly to NPs. Direct application of MitoQ-NPs, unloaded NPs or MitoQ alone did not 
affect dendrite lengths (Supplementary Fig S2e), cell number (Supplementary Fig S2f), 
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number of neurons (Supplementary Fig S2g) or number of astrocytes (Supplementary Fig 
S2h). Furthermore, MitoQ-NPs or unloaded NPs had no direct effect on cell viability of 
fibroblast (Supplementary Fig S2i). Neither MitoQ-NPs nor Gap26-NPs affected DNA 
integrity in fibroblasts (Supplementary Fig S2j). Direct application of Gap26-NPs, but not 
MitoQ-NPs, reduced the amount of DNA damage in fibroblasts caused by direct exposure to 
benzoquinone and hydroquinone (Supplementary Fig S2j), suggesting that some of the DNA 
damage might be caused by bystander signalling through connexin channels within the 
fibroblast cultures42. Furthermore, the BeWo barriers showed high integrity (Supplementary 
Fig S2k), confirming that NP-bound drugs were unable to pass through gaps between the 
cells to directly affect fibroblast and cortical cultures. 
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Supplementary Methods 
Nanoparticles 
An amphiphilic copolymer of poly(γ-glutamic acid) and L-phenylalanine ethylester(γ-PGA-
Phe) was synthesized as described previously80 using a 50% Phe grafting degree. 10 mg/mL 
of γ-PGA-Phe was dissolved in DMSO, added to equivalent volume of 0.15 M NaCl and 
dialyzed against distilled water. Dialyzed solutions were freeze-dried and resuspended in PBS 
(10 mg/mL). NPs were measured by dynamic light scattering (Zetasizer Nano ZS, Malvern 
Instruments, UK) as 180 nm diameter, polydispersity index 0.12, Zeta potential -20 mV. 
γ-PGA-Phe NPs (10 mg/mL) were mixed with Gap26 (2 mg/mL), MitoQ (2 mg/mL) or C17 
(0.5 mg/mL) at equivalent volume in 0.2 M NaCl, and incubated at 4°C for 12 h. NPs were 
isolated by centrifugation, washed and resuspended in PBS to 10 mg/mL. The amount of drug 
which was adsorbed to NPs was evaluated by the Lowry method for Gap26, and UV 
absorption measurement for MitoQ (278 nm) and C17 (331 nm). The adsorption efficiency 
(%) was calculated as (adsorbed drug weight/initial feeding weight) × 100. Drug loading was 
calculated as loaded drug weight (μg)/NP weight (mg). Release of drug from NPs in vitro 
was calculated by immersing them in PBS or culture medium with 10% FCS and measuring 
the drug in the supernatant. 
 
Measurement of cell viability and DNA damage in fibroblasts 
Primary human BJ skin fibroblasts (ATCC CRL-2522) were grown in Minimal Essential 
Medium (Sigma-Aldrich), supplemented with 10% FBS, 2% HEPES buffer (Sigma-Aldrich), 
1 mM sodium pyruvate solution (Thermo Fisher Scientific), 100 U/mL penicillin-
streptomycin and 2 mM L-glutamine. Conditioned media from BeWo barriers exposed to 
hypoxia-reoxygenation or to 30 μM hydroquinone and 30 μM benzoquinone with and 
without NPs for 24 h were applied to fibroblasts to assess cell viability by Trypan Blue assay 
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and DNA damage by alkaline comet assay, as described previously40,41. The DNA damage 
was measured using the mean tail moment as defined by the product of comet length and tail 
intensity. 
 
Nanoparticle Tracking Analysis 
Extracellular vesicles were extracted from conditioned medium using the Total Exosome 
Isolation Reagent (Thermo Fisher Scientific), according to manufacturer’s instructions, and 
resuspended in 100 μl PBS. Samples were measured using the Nanosight NS500 NTA 
instrument (Malvern Instruments, UK). Ten consecutive 30-second recordings were made for 
each sample and processed using the NTA 2.3 software (Nanosight Ltd.). Prior to analysis, 
the instrument was calibrated using reference silica and polystyrene nanospheres. 
 
Proteomic analysis 
TMT Labelling and high pH reversed-phase chromatography 
Experimental samples were depleted of albumin using a Pierce Albumin Depletion Kit 
(following the protocol for rat albumin). For the fetal plasma samples, a pooled ‘standard’ 
was then generated by combining an equal aliquot (6 μg) of each of these albumin-depleted 
samples. 40 µg of each experimental sample or the pooled standard was then digested with 
trypsin (2.5 µg trypsin per 100 µg protein; 37°C, overnight) and labelled with Tandem Mass 
Tag (TMT) 10plex reagents according to the manufacturer’s protocol (Thermo Fisher 
Scientific, Loughborough, UK) and the labelled samples were pooled. 
An aliquot of the pooled sample was evaporated to dryness and resuspended in buffer A 
(20 mM ammonium hydroxide, pH 10) prior to fractionation by high pH reversed-phase 
chromatography using an Ultimate 3000 liquid chromatography system (Thermo Fisher 
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Scientific). In brief, the sample was loaded onto an XBridge BEH C18 Column (130 Å, 
3.5 µm, 2.1 mm x 150 mm, Waters, UK) in buffer A and peptides eluted with an increasing 
gradient of buffer B (20 mM Ammonium Hydroxide in acetonitrile, pH 10) from 0-95% over 
60 minutes. The resulting fractions were evaporated to dryness and resuspended in 1% formic 
acid prior to analysis by nano-LC MS/MS using an Orbitrap Fusion Tribrid mass 
spectrometer (Thermo Scientific). 
Nano-LC Mass Spectrometry 
High pH RP fractions were further fractionated using an Ultimate 3000 nanoHPLC system in 
line with an Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific). In brief, peptides 
in 1% (vol/vol) formic acid were injected onto an Acclaim PepMap C18 nano-trap column 
(Thermo Scientific). After washing with 0.5% (vol/vol) acetonitrile 0.1% (vol/vol) formic 
acid peptides were resolved on a 250 mm × 75 μm Acclaim PepMap C18 reverse phase 
analytical column (Thermo Scientific) over a 150 min organic gradient, using 7 gradient 
segments (1-6% solvent B over 1 min, 6-15% B over 58 min, 15-32% B over 58 min, 32-40% 
B over 5 min., 40-90% B over 1 min, held at 90% B for 6 min and then reduced to 1% B over 
1 min) with a flow rate of 300 nL min−1. Solvent A was 0.1% formic acid and Solvent B was 
aqueous 80% acetonitrile in 0.1% formic acid. Peptides were ionized by nano-electrospray 
ionization at 2.0 kV using a stainless steel emitter with an internal diameter of 30 μm 
(Thermo Scientific) and a capillary temperature of 275°C.  
All spectra were acquired using an Orbitrap Fusion Tribrid mass spectrometer controlled by 
Xcalibur 2.0 software (Thermo Scientific) and operated in data-dependent acquisition mode 
using an SPS-MS3 workflow. FTMS1 spectra were collected at a resolution of 120,000, with 
an automatic gain control (AGC) target of 200,000 and a max injection time of 50 ms. The 
Top N most intense ions were selected for MS/MS. Precursors were filtered according to 
charge state (to include charge states 2-7) and with monoisotopic precursor selection. 
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Previously interrogated precursors were excluded using a dynamic window (40 s +/-10 ppm). 
The MS2 precursors were isolated with a quadrupole mass filter set to a width of 1.2 m/z. 
ITMS2 spectra were collected with an AGC target of 5,000, max injection time of 120 ms 
and CID collision energy of 35%. 
For FTMS3 analysis, the Orbitrap was operated at 60,000 resolution with an AGC target of 
50,000 and a max injection time of 120 ms. Precursors were fragmented by high energy 
collision dissociation (HCD) at a normalised collision energy of 55% to ensure maximal 
TMT reporter ion yield. Synchronous Precursor Selection (SPS) was enabled to include up to 
5 MS2 fragment ions in the FTMS3 scan. 
Data Analysis 
The raw data files were processed and quantified using Proteome Discoverer software v1.4 
(Thermo Scientific) and searched against the UniProt Rat database using the SEQUEST 
algorithm. Peptide precursor mass tolerance was set at 10 ppm, and MS/MS tolerance was set 
at 0.6 Da. Search criteria included oxidation of methionine (+15.9949) as a variable 
modification and carbamidomethylation of cysteine (+57.0214) and the addition of the TMT 
mass tag (+229.163) to peptide N-termini and lysine as fixed modifications. Searches were 
performed with full tryptic digestion and a maximum of 1 missed cleavage was allowed. The 
reverse database search option was enabled and all peptide data was filtered to satisfy false 
discovery rate (FDR) of 5%. 
 
Bioinformatics analyses 
Analysis of NanoString data 
NanoString nCounter data consist of discrete sequence counts as a measure of miRNA 
expression within each sample. These counts are similar to counts from other high-
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throughput methods such as RNA sequencing, where discrete statistical models such as the 
Poisson or negative binomial distributions may be used to estimate differences between 
samples99,100. Consequently, differential expression prediction methods originally designed 
for RNA sequencing data may also be used with NanoString data101. Following the 
procedures outlined in101, we developed the following pipeline to assess DE-miRNA between 
samples: First, we converted each raw NanoString output file into a list of counts. Next we 
merged the counts for the replicates in each sample into a table with one column per 
replicate. To compare two samples, we merged the corresponding tables into a single table 
that we then passed into our differential expression analysis pipeline. 
Differential expression analysis of NanoString and RNA sequencing data 
RUVSeq was used to remove unwanted variation102 and then edgeR100 to predict 
differentially-expressed RNAs (miRNAs in the case of NanoString data, mRNAs in the case 
of RNA sequencing data). We selected edgeR for our pipeline as it may be more sensitive 
than DESeq100,103,104 and it facilitates the use of RUVSeq102. We used RUVSeq to eliminate, 
as far as possible, variation from sources unrelated to the treatment groups, such as 
differences in blood plasma collection, centrifugation, enrichment, and RNA purification. We 
expected no differential expression between replicates within a treatment group and few 
differentially-expressed RNAs between treatment groups, so the relative log-expression 
should be consistent across all samples. In addition, the largest component of variation in the 
data should reflect RNAs that are differentially expressed between treatment groups. For each 
comparison, we first used RUVSeq to adjust the counts to account for unwanted variation, 
then used the adjusted counts with edgeR’s generalized linear model to yield the final 
predictions. 
To mitigate possible false-positives, miRNAs were classed as significant differentially 
secreted miRNAs if p < 0.05, if count ≥ 10 for at least one of the compared conditions 
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(except for fetal plasma miRNAs were counts were generally very low) and if there was an 
up or down regulation of at least 25%. 
Analysis of miRNA-mRNA correlation 
Enrichment analysis of the RNA sequencing data for predicted targets (derived from 
TargetScanHuman83) of significant miRNAs was performed in R/Bioconductor using the 
Fisher’s exact test and investigating enrichment only. Correlation of abundance changes of 
significant miRNAs with abundance changes of significant mRNAs was analysed with the 
miRComb105 package for R/Bioconductor, using Spearman correlation and Benjamini-
Hochberg adjustment for multiple comparisons.  
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Supplementary Figures 
 
Supplementary Figure S1 | Further characterisation of drug delivery NPs. a, Adsorption 
efficiency of different drugs to NPs (total adsorbed drug weight to NPs/initial feeding amount 
of drug weight) × 100 (n = 3 experiments). b, Amount of drug (µg) loaded to 1 mg of NPs. c, 
Rate of adsorption of increasing concentrations of Gap 26 and MitoQ to 1 mg of NPs. d, 
Release with time of Gap26 and MitoQ from NPs into PBS (n = 3). e, Release with time of 
Gap26 from NPs into PBS or culture medium containing 10% fetal calf serum (n = 3 
biological replicates). All measurements are means ± s.e.m. 
 
Supplementary Figure S2 | Effects of different drug delivery-NPs on the secretions from 
model trophoblast barriers in vitro. a-d, Levels of DNA damage, as recorded by an 
increase in mean tail moment (product of comet length and tail intensity) using the alkaline 
comet assay, in fibroblasts (a,b) or dendrite lengths of dissociated cortical neurons (c,d) after 
exposure to conditioned media or normal tissue culture medium (Control, C). Conditioned 
media was collected from bilayered BeWo barriers following 24 h exposure to atmospheric 
oxygen (21%), hypoxia followed by partial reoxygenation (2-12%) or hypoxia followed by 
full reoxygenation (2-21%) (a-c), or to 30 µM benzoquinone/30 µM hydroquinone (BQ/HQ) 
(d). Barriers were treated with unbound NPs, drug-loaded NPs or soluble drug on its own. e, 
Dendrite lengths in dissociated cortical neurons after direct exposure to NPs with or without 
drug. f-h, Effect of direct application of unbound MitoQ, blank NPs or MitoQ-NPs on total 
cell number (f), neuron count (g) and astrocyte count (h) of rat cortical cultures. i, Cell 
viability of fibroblasts directly exposed to 0.5 μM or 5 μM MitoQ-NPs or NPs alone, as 
recorded with the Trypan blue assay. j, DNA damage in fibroblasts 24 h after direct exposure 
to BQ/HQ and unbound or drug-containing NPs. k, Percentage of applied FITC-BSA 
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detected below a bilayered BeWo grown at atmospheric oxygen (21%), hypoxia (2%) or 
hypoxia followed by reoxygenation (2-12%), 1 h after addition of FITC-BSA to the medium 
above the barrier. As a positive control, FITC-BSA was measured in the Transwell insert. 
Differences in concentration between the media below the barrier and the medium in the 
insert were significant for all oxygen conditions. Replicates (separate in vitro experiments) 
per condition: (a, b, j) n = 9; (c, d) n = 15; (e) n = 10 for C and C+NP, n = 9 for C+MitoQ; (f) 
n = 43, 5, 23, 34 from left to right; (g) n = 44; 5, 9, 17; (h) n = 74, 10, 5, 5; (i,k) n = 3. *p < 
0.05, **p < 0.01, ***p < 0.001 using one-way ANOVA with Bonferroni correction for 
multiple comparisons. For clarity, not all significant differences are shown. All measurements 
are means ± s.e.m. 
 
Supplementary Figure S3 | Further analysis of effects of drug delivery NPs in vivo. 
Effects of in vivo exposure to gestational normoxia (21%) or hypoxia (11%) with maternal 
injection of saline or MitoQ-NPs were investigated. a, Brain weight of offspring at 
gestational day 20 (top; n = 3 litters) or postnatal day 30 (bottom; n = 24 individuals). b, 
Diameter of labyrinth (top) and decidua zones (bottom) of the placenta (number of biological 
replicates from left to right: n = 22, 16, 10, 12). c, Confocal images of rat maternal liver and 
cortex after maternal injection with saline or fluorescent NPs (green), counterstained with 
DAPI (blue), scale bar = 100 μm. The high density of NP within the cortex, as shown in the 
image, was found in sparsely distributed areas throughout the maternal brain. c, Light 
micrographs showing the gross histology (H&E stain) of the placental labyrinth at GD20 
following in vivo normoxia or hypoxia with maternal saline or MitoQ-NP injection (scale bar 
= 2 μm). d, Immunostaining of placental blood vessels in the labyrinth with anti-CD34 
antibody (scale bar = 50 μm). e, Number of blood vessels per field of view (top; n = 3) and 
total perimeter of blood vessels, normalised to control levels, per field of view (bottom; n = 
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3). f, Levels of fluorescent DCF in the labyrinth (top) and the junctional zones (bottom) of the 
placenta (n = 6) as well as in cortex (top) and cerebellum (bottom) of the fetus (n = 6). All 
measurements are means ± s.e.m. 
 
Supplementary Figure S4 | Further analysis of secretions from the placental barrier 
after application of drug delivery NPs. a, Total levels of small RNAs and miRNAs in 
media conditioned by BeWo barriers exposed to different oxygen tensions for 24 h (n = 3 
experiments). b, Analysis of particle sizes and concentrations in conditioned media collected 
from below BeWo barriers exposed to varying levels of oxygen with or without MitoQ-NP 
application. The grey bar delimits particles of 50-150 nm in size, which includes the size 
range of exosomal vesicles. c, Total levels of small RNAs and miRNAs in culture media 
conditioned by rat placenta. Placentas had been exposed to gestational normoxia or hypoxia 
following maternal administration of saline or MitoQ-NPs and were subjected to 24 h 
exposure to 21% or 2% oxygen tension ex vivo (Normoxia+Saline, n = 3 biological replicates 
from different dams; all other conditions, n = 4). d, The effect of maternal MitoQ-NP 
injection (orange) on those miRNAs that showed significantly different levels under hypoxic 
conditions (blue) is depicted as log2 fold change, compared to control conditions (normoxia, 
no NPs). Extracted placentas were additionally exposed to 21% (top) or 2% oxygen (bottom) 
ex vivo. e, Levels of total amino acids in medium conditioned by rat placentas exposed to 
maternal normoxia, M(21%), or hypoxia, M(11%), following maternal administration of 
saline or MitoQ-NPs. To discover any potentially masked effects of amino acid secretion 
from the placenta, medium diluted 1:2 with PBS was compared with undiluted medium. All 
measurements are means ± s.e.m. 
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Supplementary Figure S5 | Analysis of fetal neurons after indirect exposure to hypoxia 
and drug delivery NPs. Cortical cultures analysed following exposure to media conditioned 
by BeWo barriers (a,c,e,g) or rat placenta (b,d,f,h). BeWo barriers had been exposed to 21%, 
8% or 2-12% oxygen. Placentas had been exposed to maternal normoxia, M(21%), or 
hypoxia, M(11%), for 6 d with maternal saline or MitoQ-NP injection and to different oxygen 
levels ex vivo (21%, 2%). a,b, Length of dendritic processes (number of biological replicates 
from left to right: a, n = 25, 15; b, n = 14, 14, 13, 20, 41, 29). c,d, Process length of TH-
positive cells (c, n = 25, 15; d, n = 60, 30, 15, 9, 27, 15). e,f, Staining intensity of GluN1 
subunits, normalised to control levels (e, n = 15, 8; f, n = 76, 46, 28, 36, 51, 40). g,h, Ratio of 
astrocytes to neurons (g, n = 25, 15; h, n = 20, 40, 15, 35, 47, 35). Significant differences 
determined using ANOVA with Tukey’s test to correct for multiple comparisons (*p < 0.05, 
**p < 0.01, ***p < 0.001). All measurements are means ± s.e.m. 
 
Supplementary Figure S6 | Neuronal cell count after indirect exposure to maternal 
hypoxia and drug delivery NPs. a-e, Total cell number in vitro following exposure of 
cortical cultures to rat placenta conditioned media (a-b; number of biological replicates from 
left to right: a, n = 10, 10, 8, 10; b, n = 23, 20, 35, 35, 41, 41) or fetal plasma (c; n = 10), and 
in vivo in thalamic reticular nucleus (TRN, h; n = 35, 51, 55, 43) and in somatosensory, 
auditory and retrosplenial cortex combined (CTX, i; n = 63, 126, 126, 98) of the offspring. f-
j, Number of tyrosine hydroxylase (TH)-positive neurons in vitro following exposure of 
cortical cultures to rat placenta conditioned media (f-g; f, n = 12, 10, 8, 10; g, n = 5) or fetal 
plasma (h; n = 5), and in vivo in TRN (i; n = 64, 56, 60, 44) and CTX (j; n = 121, 108, 123, 
98) of the offspring. Offspring had been exposed in vivo to maternal normoxia, M(21%), or 
hypoxia, M(11%), along with maternal injection of saline or MitoQ-NPs. Conditioned media 
were obtained after ex vivo incubation of extracted placenta for 24 h at different oxygen 
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levels (8%, 21%, 2%). ANOVA with correction for multiple comparisons using Tukey’s test 
was used to detect significant differences (*p < 0.05). All measurements are means ± s.e.m. 
 
Supplementary Figure S7 | Diagram of experimental set-up and outcomes of hypoxia 
and MitoQ-NP injection in vitro and in vivo. Presented are the observed effects of maternal 
hypoxia and maternal MitoQ-NP i.v. injection on levels of reactive oxygen species (ROS) in 
fetal and maternal tissues and placenta as well as on structural and transcriptome changes in 
the offspring brain. Observed effects of conditioned medium from rat placenta or of fetal 
plasma following maternal hypoxia and MitoQ-NP exposure on cortical cultures are also 
shown, along with effects of conditioned medium from directly exposed BeWo barriers. 
Interrupted arrow indicates potential interaction between secreted miRNAs and transcriptome 
changes in the fetal brain. 
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Supplementary Tables 
 
Supplementary Table S1 | MitoQ concentration in conditioned media. Concentration of 
soluble MitoQ was measured in conditioned medium collected from below BeWo barriers 
that had been exposed to 2-12% oxygen with or without application of 0.5 μM MitoQ-NP to 
the top of the barrier. MitoQ was also quantified in medium conditioned by placentas 
collected from dams exposed to gestational hypoxia combined with injection of MitoQ-NP 
(0.5 μM blood concentration) or saline. MitoQ concentration is displayed in pM and as % of 
original exposure. All measurements are means ± s.e.m. Significance was calculated using 
student’s t-test. 
 
Supplementary Table S2 | Amino acid concentrations in hypoxia-conditioned media 
from rat placenta. Placentas were exposed to maternal hypoxia combined with atmospheric 
oxygen conditions or 2% oxygen for 24 h ex vivo. Either saline or MitoQ-NP were maternally 
injected at the start of in vivo exposure. Amino acid concentrations in μmol/L (s.e.m.) were 
measured in the surrounding conditioned medium. #p < 0.05, ##p < 0.01; significant compared 
to saline condition of the respective oxygen condition. 
 
Supplementary Table S3 | Amino acid concentrations in hypoxia-conditioned media 
from rat placenta. Placenta were exposed to maternal hypoxia combined with 8% oxygen 
for 24 h ex vivo. Either saline or MitoQ-NP were maternally injected at the start of in vivo 
exposure. Amino acid concentrations in μmol/L (s.e.m.) were measured in the surrounding 
conditioned medium. No significant differences were detected. 
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Supplementary Table S4 | Amino acid concentrations in hypoxia-conditioned media 
from rat placenta. Placenta were exposed to maternal hypoxia combined with 21% oxygen 
for 24 h ex vivo. Either saline or MitoQ-NP were maternally injected at the start of in vivo 
exposure. Amino acid concentrations in μmol/L (s.e.m.) were measured in the surrounding 
conditioned medium. Culture medium was diluted with PBS prior to exposure to estimate the 
contribution of placenta-secreted amino acids compared to those already present in the 
culture medium. *p < 0.05; significant compared to normoxia saline condition. 
 
Supplementary Table S5 | Enrichment of predicted mRNA targets for genes associated 
with schizophrenia copy number variants. Predicted targets of miRNAs that were found to 
be significantly up or down-regulated in rat placenta conditioned media or fetal plasma, under 
gestational hypoxia compared to normoxia, were analysed for enrichment of copy number 
variants associated with schizophrenia. Placental tissue and fetal plasma were collected 
following maternal exposure to hypoxia; placentas were incubated at 8%, 21% or 2% oxygen 
ex vivo. p values and p values corrected for multiple comparisons are given. p < 0.05 are 
highlighted in bold. 
 
Supplementary Table S6 | Enrichment of predicted miRNA targets for genes associated 
with schizophrenia copy number variants, conditioning on a minimal gene set. Predicted 
targets of miRNAs that were found to be significantly up or down-regulated in rat placenta 
conditioned media or fetal plasma, under gestational hypoxia compared to normoxia, were 
analysed for enrichment of copy number variants associated with schizophrenia. Analysis 
was conditioned on the ‘minimal’ gene sets previously shown to capture CNS-related gene 
set enrichment. Placental tissue and fetal plasma were collected following maternal exposure 
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to hypoxia; placentas were incubated at 8%, 21% or 2% oxygen ex vivo. p < 0.05 are 
highlighted in bold. 
 
Supplementary Table S7 | Enrichment of fetal brain transcriptome for miRNA targets. 
Gene transcripts that were significantly altered in the fetal brain following hypoxia were 
analysed for enrichment of predicted miRNA targets. Predicted targets were analysed of 
those miRNAs that were significantly altered in conditioned medium from rat placenta or in 
fetal plasma, following gestational hypoxia. p values were calculated using Fisher’s exact 
test. 
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Supplementary Table S1 
 
Original exposure: 
NP-bound MitoQ in pM 
(concentration above 
barrier or blood 
concentration) 
MitoQ concentration in 
pM (% exposure) 
 
 Saline MitoQ-NP Significance 
BeWo conditioned 
medium 
5x105 0.32±0.21  
(6.54x10-7) 
0.19±0.13 
(3.82x10-7) 
ns 
Rat placenta  
conditioned medium 
5x105 
0.11±0.01 
(2.10x10-7) 
0.12±0.03 
(2.40x10-7) 
ns 
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Supplementary Table S2 
 M(21%) + 21% M(11%) + 21% M(11%) + 2% 
 Saline MitoQ-NP Saline 
MitoQ-
NP 
Saline MitoQ-NP 
Alanine 
1390.7 
(204.6) 
2118.7 
(398.1) 
997.7 
(115.7) 
1574.5# 
(59.5) 
923.3 
(75.11) 
1364.0 
(304.0) 
Arginine 
473.0 
(132.7) 
670.3 
(150.4) 
343.7 
(94.6) 
353.5 
(85.6) 
181.0 
(63.6) 
69.0  
(2.8) 
Aspartate 
581.0 
(26.7) 
935.0# 
(100.8) 
520.0 
(91.1) 
840.5 
(76.5) 
467.3 
(29.1) 
751.5 
(156.5) 
Citrulline 
61.7  
(4.1) 
46.3  
(23.5) 
27.0  
(22.0) 
75.5  
(5.5) 
53.3  
(22.7) 
94.5  
(3.5) 
Cysteine 
107.0 
(31.6) 
173.3 
(59.6) 
45.7  
(4.9) 
59.5 
 (30.5) 
18.0  
(6.7) 
47.0  
(1.0) 
Glutamate 
1712.7 
(205.9) 
2283.7 
(421.4) 
1259.3 
(279.8) 
2013.5 
(14.5) 
1285.7 
(207.6) 
1961.5 
(336.5) 
Glutamine 
2324.0 
(507.1) 
2521.3 
(557.1) 
1319.0 
(476.5) 
1786.5 
(36.5) 
1688.3 
(754.9) 
1782.0 
(153) 
Glycine 
1423.3 
(190.5) 
1916 
(304.6) 
1044.3 
(93.2) 
1492.5# 
(17.5) 
1051.0 
(58.80) 
1365.5 
(255.3) 
Histidine 
317.7 
(25.7) 
456.7 
(49.7) 
302.0  
(6.7) 
408.0# 
(22.0) 
271.0  
(1.5) 
341.5 
(55.5) 
Isoleucine 
942.0 
(61.1) 
1147.7 
(105.4) 
859.7 
(26.1) 
1036.5# 
(13.5) 
864.0 
(15.9) 
1038.0 
(77.0) 
Leucine 
1371.3 
(112.5) 
1809.0 
(196.1) 
1226.3 
(89.5) 
1609.5# 
(36.5) 
1182.0 
(19.3) 
1479.0 
(182.0) 
Lysine 
1332.3 
(103.8) 
1765.3 
(128.9) 
1219.3 
(38.7) 
353.5## 
(60.5) 
1199.3 
(3.3) 
1498.0 
(204.0) 
Methionine 
367.3 
(41.9) 
503.3 
(77.5) 
306.3 
(20.2) 
416.0# 
(10.0) 
300.0  
(7.1) 
391.0 
(55.0) 
Ornithine 
318.0 
(91.8) 
400.3  
(4.7) 
403.3 
(84.6) 
661.5 
(94.5) 
553.7 
(28.1) 
855.5 
(134.5) 
Phenylalanine 
653.7 
(68.0) 
873.3 
(105.1) 
577.3 
(20.2) 
769.0## 
(8.0) 
564.7 
(12.5) 
717.0 
(95.0) 
Serine 
1201.3 
(123.0) 
1665.7 
(279.1) 
1030.7 
(85.3) 
1409.5# 
(35.5) 
1007.7 
(41.5) 
1312.5 
(217.5) 
Threonine 
1199.3 
(92.1) 
1558.7 
(167.4) 
1071.3 
(47.6) 
1169.0 
(112.0) 
1034.3 
(21.2) 
1208.0 
(154.0) 
Tyrosine 
574.3 9 
(61.0) 
721.3 
(89.6) 
514.3 
(22.2) 
662.5# 
(3.5) 
511.3 
(8.3) 
633.5 
(72.5) 
Valine 
1178.7 
(91.6) 
1548.3 
(163.8) 
1064.7 
(34.4) 
1358.5 # 
(41.5) 
1021.3 
(13.3) 
1270.5 
(141.5) 
Total amino acids 
17529.3 
(1980.0) 
23114.3 
(3254.6) 
14132.0 
(1434.1) 
19295.5 
(295.5) 
14179.3 
(1112.8) 
18179.5 
(2219.5) 
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Supplementary Table S3 
 M(21%) + 8% M(11%) + 8% 
 Saline MitoQ-NP Saline MitoQ-NP 
Alanine 
3155.5 
(729.9) 
2428.9 
(461.6) 
2757.6 
(758.8) 
2391.5 
(272.2) 
Arginine 
973.4 
(250.8) 
560.0 
(79.2) 
574.0 
(307.0) 
691.3 
(108.3) 
Asparagine 
727.2 
(216.9) 
512.0 
(92.1) 
648.5 
(265.5) 
490.4 
(40.5) 
Aspartate 
990.9 
(245.8) 
760.9 
(171.8) 
919.0 
(368.1) 
870.1 
(60.1) 
Citrulline 
117.5  
(8.0) 
145.2  
(28.4) 
148.5  
(51.5) 
103.9  
(16.8) 
Cysteine 
294.9 
(63.6) 
223.2 
(25.7) 
257.0  
(48.8) 
223.6 
 (16.1) 
Glutamate 
2842.4 
(499.1) 
2551.2 
(449.3) 
2496.4 
(558.7) 
2160.7 
(214.0) 
Glutamine 
2965.5 
(335.4) 
2413.9 
(111.1) 
2502.4 
(179.1) 
2007.1 
(280.7) 
Glycine 
2407.2 
(365.8) 
2109.7 
(299.2) 
2226.5 
(472.6) 
2035.6 
(278.8) 
Histidine 
541.0 
(133.0) 
421.0 
(81.8) 
387.8  
(60.9) 
319.2 
(33.3) 
Isoleucine 
780.5 
(363.3) 
1199.5 
(128.3) 
1281.7 
(233.7) 
1014.6 
(94.9) 
Leucine 
1908.6 
(51.0) 
2019.2 
(304.0) 
2220.7 
(220.6) 
1905.8 
(186.9) 
Lysine 
2253.1 
(437.1) 
1879.7 
(269.3) 
2041.1 
(437.0) 
1648.5 
(178.6) 
Methionine 
618.9 
(124.9) 
518.4 
(80.4) 
539.8 
(128.8) 
443.8 
(37.3) 
Ornithine 
188.9 
(31.2) 
244.6  
(59.7) 
325.2 
(120.0) 
209.6 
(44.6) 
Phenylalanine 
637.7 
(303.7) 
975.9 
(137.1) 
1054.2 
(235.9) 
893.8 
(84.7) 
Proline 
1511.0 
(316.6) 
1174.7 
(255.6) 
1045.1 
(670.3) 
1208.6 
(162.0) 
Serine 
2138.1 
(461.9) 
1739.7 
(282.9) 
1938.4 
(547.7) 
1677.1 
(235.9) 
Threonine 
1912.6 
(321.8) 
1592.5 
(191.5) 
1698.6 
(326.6) 
1453.5 
(143.4) 
Tryptophan 
120.5 
(83.4) 
158.8 
(83.0) 
46.3  
(46.3) 
0  
(0) 
Tyrosine 
1675.8 
(933.1) 
783.6 
(104.0) 
827.7 
(152.3) 
683.3 
(62.8) 
Valine 
2012.0 
(388.6) 
1695.5 
(226.3) 
1823.9 
(386.8) 
1553.2 
(167.3) 
Total amino 
acids 
30773.27 
(5199.8) 
26137 
(3811.1) 
27760.7 
(6681.3) 
23985.3 
(2612.3) 
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Supplementary Table S4 
 M(21%) + 21% M(11%) + 21% 
 Saline MitoQ-NP Saline MitoQ-NP 
Alanine 
4284.9 
(539.6) 
3042.4 
(720.6) 
2661.6* 
(137.9) 
3367.3 
(219.1) 
Arginine 
423.7 
(193.3) 
802.2 
(158.7) 
503.7 
(250.0) 
829.1 
(180.3) 
Asparagine 
564.4 
(316.0) 
635.7 
(199.2) 
526.4 
(123.6) 
477.4 
(244.1) 
Aspartate 
406.6 
(271.5) 
944.5 
(263.1) 
749.5 
(94.8) 
809.7 
(204.3) 
Citrulline 
20.0  
(12.8) 
38.0 
(38.0) 
157.7 
(28.4) 
132.6  
(24.4) 
Cysteine 
174.3 
(57.8) 
241.3 
(26.2) 
307.6  
(28.4) 
271.6 
 (68.0) 
Glutamate 
3182.4 
(285.0) 
2513.1 
(470.2) 
2241.5 
(193.1) 
2672.6 
(217.1) 
Glutamine 
2898.1 
(258.7) 
3058.0 
(407.3) 
2044.8 
(259.4) 
3179.8 
(548.9) 
Glycine 
2818.4 
(262.1) 
2436.0 
(453.3) 
2250.2 
(101.3) 
2611.6 
(186.7) 
Histidine 
713.3 
(133.0) 
541.0 
(144.4) 
479.7  
(47.9) 
613.3 
(45.3) 
Isoleucine 
1338.7 
(226.5) 
1300.7 
(240.8) 
956.0 
(73.8) 
1305.2 
(73.1) 
Leucine 
2876.5 
(502.3) 
2267.9 
(480.3) 
1955.9 
(158.4) 
2438.1 
(160.1) 
Lysine 
2543.9 
(445.0) 
2043.7 
(421.5) 
1838.8 
(147.2) 
2195.6 
(150.7) 
Methionine 
720.5 
(142.4) 
582.8 
(127.8) 
446.3 
(37.2) 
573.1 
(29.7) 
Ornithine 
230.8 
(49.3) 
322.8  
(96.5) 
406.9 
(180.7) 
301.7 
(66.0) 
Phenylalanine 
1374.4 
(246.9) 
1085.2 
(221.0) 
929.4 
(74.4) 
1116.2 
(68.8) 
Proline 
1876.6 
(305.5) 
1518.1 
(352.4) 
1313.2 
(63.5) 
1573.0 
(123.9) 
Serine 
893.4 
(579.8) 
1966.5 
(433.6) 
1237.5 
(593.7) 
1730.5 
(441.6) 
Threonine 
1540.4 
(132.1) 
1806.8 
(282.1) 
1621.3 
(139.2) 
1835.5 
(118.0) 
Tryptophan 
202.0 
(117.2) 
46.6  
(46.6) 
161.1  
(24.8) 
230.4  
(37.5) 
Tyrosine 
913.3 
(171.1) 
837.3 
(152.4) 
603.0 
(234.4) 
884.5 
(65.3) 
Valine 
2186.3 
(343.4) 
1856 
(352.9) 
1570.0 
(115.3) 
2005.5 
(119.0) 
Total amino 
acids 
32182.9 
(2845.4) 
29886.4 
(5953.3) 
24962.0 
(1994.3) 
31154.2 
(2047.3) 
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Supplementary Table S5 
  Combined Deletion Duplication 
 # Genes p p corr p p corr p p corr 
Rat placenta CM (8%) 
      
All 3083 3.39E-05 1.22E-03 1.07E-01 1.00E+00 1.26E-04 4.55E-03 
Down 1565 1.77E-03 6.36E-02 9.58E-03 3.45E-01 3.38E-02 1.00E+00 
Up 2005 1.08E-04 3.87E-03 1.14E-01 1.00E+00 5.00E-04 1.80E-02 
Rat placenta CM (21%) 
      
All 1495 3.95E-03 1.42E-01 1.69E-02 6.07E-01 6.00E-02 1.00E+00 
Down 665 5.43E-01 1.00E+00 3.63E-01 1.00E+00 7.93E-01 1.00E+00 
Up 917 6.72E-04 2.42E-02 1.78E-03 6.41E-02 3.09E-02 1.00E+00 
Rat placenta CM (2%) 
      
All 2895 3.02E-04 1.09E-02 7.55E-05 2.72E-03 9.07E-02 1.00E+00 
Down 771 1.06E-02 3.82E-01 2.30E-05 8.30E-04 6.02E-01 1.00E+00 
Up 2400 3.05E-05 1.10E-03 3.70E-05 1.33E-03 2.72E-02 9.80E-01 
Fetal plasma 
      
All 1265 1.07E-02 3.84E-01 1.18E-03 4.23E-02 3.54E-01 1.00E+00 
Down 599 5.15E-02 1.00E+00 2.43E-04 8.74E-03 7.00E-01 1.00E+00 
Up 727 3.50E-02 1.00E+00 1.19E-01 1.00E+00 1.40E-01 1.00E+00 
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Supplementary Table S6 
  Combined Deletion Duplication 
 # Genes coeff p value coeff p value coeff p value 
Rat placenta CM (8%) 
      
All 3083 + 5.18E-03 + 1.27E-01 + 1.21E-02 
Down 1565 + 1.99E-02 + 4.23E-02 + 1.25E-01 
Up 2005 + 2.01E-03 + 7.43E-02 + 1.00E-02 
Rat placenta CM (21%) 
      
All 1495 + 3.62E-02 + 6.12E-02 + 1.81E-01 
Down 665 - 5.75E-01 - 8.32E-01 - 6.28E-01 
Up 917 + 1.32E-02 + 7.45E-03 + 1.96E-01 
Rat placenta CM (2%) 
      
All 2895 + 1.47E-02 + 3.38E-02 + 2.28E-01 
Down 771 + 1.01E-01 + 1.43E-01 - 5.93E-01 
Up 2400 + 1.64E-03 + 9.63E-03 + 6.96E-02 
Fetal plasma 
      
All 1265 + 8.59E-02 + 5.29E-02 - 5.24E-01 
Down 599 + 5.41E-02 + 1.14E-02 - 5.31E-01 
Up 727 + 2.85E-01 + 3.30E-01 + 4.48E-01 
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Supplementary Table S7 
 
% targets  
of significant 
genes 
% targets  
of all genes 
Fold 
enrichment 
p value 
Rat placenta 
conditioned medium 
12.72 11.04 1.15 0.003 
Fetal plasma 10.53 9.28 1.13 0.013 
 
 
 
